Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Mediastinal grey zone lymphoma, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
No randomised trial has been run in this entity and none is likely: it is about one lymphoma in 250, so the evidence will stay observational.
Pathologists disagree about the boundary with nodular sclerosis classic Hodgkin lymphoma more often than about almost any other lymphoma boundary, and the treatment that follows the two diagnoses is different.
Whether radiotherapy to a residual mediastinal mass adds anything after modern immunochemotherapy has not been tested here.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
The diagnosis needs a generous biopsy, because the appearance varies across a single tumour and a core needle may sample only the part that looks like one of the neighbouring diseases. Both 2022 classifications require involvement of the mediastinum: an identical-looking tumour elsewhere in the body is diffuse large B-cell lymphoma, not otherwise specified. A nodular sclerosis classic Hodgkin lymphoma with variable CD20 expression remains Hodgkin lymphoma and is not reclassified here.
WHO-HAEM5 and the International Consensus Classification both adopted the name mediastinal grey zone lymphoma and both reassigned non-mediastinal cases to diffuse large B-cell lymphoma, not otherwise specified.
Sequencing showed that cases arising outside the mediastinum carry different gene expression profiles and DNA alterations from those arising in it, which is the evidence both 2022 classifications used to restrict the name.
The fourth edition of the WHO classification created B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma, which could be diagnosed at any site.